ONC201 induces cell death in pediatric non- Hodgkin’s lymphoma cells

Cell Cycle

Volumn 14, Issue 15, 2015, Pages 2422-2428

  Talekar, Mala K ^a   Allen, Joshua E ^b   Dicker, David T ^c   El Deiry, Wafik S ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b Oncoceutics   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Cancer; Lymphoma; NHL; ONC201; TIC10; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BIOLOGICAL MARKER; BORTEZOMIB; CYTARABINE; DEATH RECEPTOR 5; DOXORUBICIN; ONC 201; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS; TIC10 COMPOUND; TNFRSF21 PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL VIABILITY; CHILDHOOD CANCER; DNA CONTENT; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; NON-HODGKIN LYMPHOMA CELL LINE; PROTEIN EXPRESSION; TREATMENT RESPONSE; CELL SURVIVAL; CHILD; DRUG EFFECTS; LYMPHOMA, NON-HODGKIN; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL SURVIVAL; CHILD; CYTARABINE; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LYMPHOMA, NON-HODGKIN; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84943811613     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1054086     Document Type: Article

References (34)

1. Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2010; 184: 16-20; PMID: 19857474; http://dx. doi. org/10. 1016/j. cbi. 2009. 10. 009.
2. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vernon SW, Cronin K, Edwards BK. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88: 2398-424; PMID: 10820364; http://dx. doi. org/10. 1002/(SICI)1097-0142(20000515)88: 10%3 c2398:: AID-CNCR26%3e3. 0. CO; 2-I.
3. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996; 334: 1238-48; PMID: 8606720; http://dx. doi. org/10. 1056/NEJM199605093341906.
4. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356-61; http://dx. doi. org/10. 4049/jimmunol. 168. 3. 1356.
5. Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology 2009; 127: 145-54; PMID: 19476510; http://dx. doi. org/10. 1111/j. 1365-2567. 2009. 03058. x.
6. Crowder RN, El-Deiry WS. Caspase-8 regulation of TRAIL-mediated cell death. Exp Oncol 2012; 34: 160-4; PMID: 23070000.
7. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin-and bortezomib-induced cell death. Br J Haematol 2005; 130: 501-10; PMID: 16098063; http://dx. doi. org/10. 1111/j. 1365-2141. 2005. 05656. x.
8. Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, et al. Initial testing (stage 1) of mapatumumab (HGSETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 54: 307-10; PMID: 19856388.
9. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 8628-33; PMID: 14634624; http://dx. doi. org/10. 1038/sj. onc. 1207232.
10. Fox NL, Humphreys R, Luster TA, Klein J, Gallant G. Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. Expert Opin Biol Ther 2010; 10: 1-18; PMID: 19857186; http://dx. doi. org/10. 1517/14712590903319656.
11. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Exp Opin Ther Targets 2010; 14: 1091-108; PMID: 20819019; http://dx. doi. org/10. 1517/14728222. 2010. 519701.
12. Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP, Gogineni A, Cole MJ, Yee SF, Ross S, et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007; 110: 4037-46; PMID: 17724141; http://dx. doi. org/10. 1182/blood-2007-02-076075.
13. Mouzakiti A, Packham G. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br J Haematol 2003; 122: 61-9; PMID: 12823346; http://dx. doi. org/10. 1046/j. 1365-2141. 2003. 04424. x.
14. Hussain A, Doucet JP, Gutierrez M, Ahmad M, Al-Hussein K, Capello D, Gaidano G, Bhatia K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt's lymphomas with loss of multiple pro-apoptotic proteins. Haematologica 2003; 88: 167-75; PMID: 12604406.
15. Ucur E, Mattern J, Wenger T, Okouoyo S, Schroth A, Debatin KM, Herr I. Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells. Br J Cancer 2003; 89: 2155-62; PMID: 14647152; http://dx. doi. org/10. 1038/sj. bjc. 6601407.
16. Gasparini C, Vecchi Brumatti L, Monasta L, Zauli G. TRAIL-based therapeutic approaches for the treatment of pediatric malignancies. Curr Med Chem 2013; 20: 2254-71; PMID: 23458616; http://dx. doi. org/10. 2174/0929867311320170009.
17. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13: 1070-7; PMID: 17767167; http://dx. doi. org/10. 1038/nm1627.
18. Stern HM, Padilla M, Wagner K, Amler L, Ashkenazi A. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clin Cancer Res 2010; 16: 1587-96; PMID: 20179215; http://dx. doi. org/10. 1158/1078-0432. CCR-09-3108.
19. - xL. J Immunol 2008; 181: 1001-11; http://dx. doi. org/10. 4049/jimmunol. 181. 2. 1001.
20. Gallouet AS, Travert M, Bresson-Bepoldin L, Guilloton F, Pangault C, Caulet-Maugendre S, Lamy T, Tarte K, Guillaudeux T. COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAILmediated apoptosis. Clin Cancer Res 2014; 20: 2663-73; PMID: 24637636; http://dx. doi. org/10. 1158/1078-0432. CCR-13-2305.
21. Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther 2012; 11: 2087-95; PMID: 22802267; http://dx. doi. org/10. 1158/1535-7163. MCT-12-0366.
22. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013; 5: 171ra17; PMID: 23390247; http://dx. doi. org/10. 1126/scitranslmed. 3004828.
23. Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAIL-dependent manner. Cancer Res 2015; 75 (7): 1423-32; http://dx. doi. org/10. 1158/0008-5472. CAN-13-3451.
24. Chargari C, Cosset JM. [The issue of low doses in radiation therapy and impact on radiation-induced secondary malignancies]. Bull Cancer 2013; 100: 1333-42; PMID: 24257106.
25. Henry M, Savasan S. Controversies in the role of radiotherapy in the treatment of pediatric Hodgkin lymphoma. Ind J Pediatr 2013; 80: 863-9; PMID: 23975267; http://dx. doi. org/10. 1007/s12098-013-1106-8.
26. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y, El-Deiry WS. Death induction by recombinant nativeTRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 2004; 279: 40044-52; PMID: 15226295; http://dx. doi. org/10. 1074/jbc. M404541200.
27. Allen JE, Prabhu VV, Talekar M, van den Heuvel P, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and pharmacological screens converge in identifying FLIP, BCL2 and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anti-cancer agent ONC201/TIC10. Cancer Res 2015; 75(8): 1668-74; http://dx. doi. org/10. 1158/0008-5472. CAN-14-2356.
28. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001; 20: 5595-610; PMID: 11607812; http://dx. doi. org/10. 1038/sj. onc. 1204595.
29. Klefstrom J, Verschuren EW, Evan G. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. J Biol Chem 2002; 277: 43224-32; PMID: 12202489; http://dx. doi. org/10. 1074/jbc. M206967200.
30. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004; 24: 8541-55; PMID: 15367674; http://dx. doi. org/10. 1128/MCB. 24. 19. 8541-8555. 2004.
31. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Devel 2000; 14: 2501-14; PMID: 11018017; http://dx. doi. org/10. 1101/gad. 836800.
32. Ishizawa J, Kojima K, Chachad D, Ruvolo PP, Ruvolo VR, Jacamo R, Dilip A, Mu H, Zeng Z, Matre P, et al. ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition. 2014.
33. Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathwayinducing compound, determines its potent anti-cancer activity. Oncotarget 2014; 5: 12728-37; PMID: 25587031.
34. Rao J, Zhang RY, Chen Y, Chen GA, Xiao CJ. [Combined effect of TNF-related apoptosis induced ligand and Ara-C in inducing apoptosis of HL-60 cells and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Xhi 2008; 16: 510-5.